Sugi Predict

Sugi Predict / Compounds / SCHEMBL29959459

SCHEMBL29959459

SCHEMBL29959459

Cc1cccc(C(=O)Cc2ccnc3ccccc23)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.49
▸ P2RX7 Q99572 1/20 0.43
▸ LOXL2 Q9Y4K0 1/20 0.43
▸ HTT P42858 2/20 0.40
▸ GALR3 O60755 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ TGFBR1 P36897 2/20 0.40
▸ MAPK14 Q16539 2/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ GRM5 P41594 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5235225 1.00 CYP1A2 (0.49) CYP1A2P2RX7LOXL2HTTGALR3
SCHEMBL5233274 0.86 CYP1A2 (0.55) CYP1A2LOXL2HTTPDE4APTGDR2
SCHEMBL3747756 0.85 ALDH1A1 (0.39) P2RX7HTTRAB9ASMN1; SMN2TGFBR1
SCHEMBL24322279 0.85 CDK8 (0.39) P2RX7RAB9ASMN1; SMN2TGFBR1GRM5
SCHEMBL31461243 0.85 ALDH1A1 (0.39) P2RX7HTTRAB9ASMN1; SMN2TGFBR1
SCHEMBL29959944 0.84 CYP1A2 (0.47) CYP1A2LOXL2HTTPDE4ATGFBR1
SCHEMBL5234356 0.84 CYP1A2 (0.47) CYP1A2LOXL2HTTPDE4ATGFBR1
SCHEMBL4872415 0.84 CYP1A2 (0.49) CYP1A2LOXL2HTTSMN1; SMN2PDE4A
SCHEMBL5236988 0.84 CYP1A2 (0.49) CYP1A2LOXL2HTTPDE4APTGDR2
SCHEMBL5236887 0.84 CYP1A2 (0.49) CYP1A2LOXL2HTTPDE4ATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116323601-B 2- (3-Pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 阿戈麦布西班牙股份有限公司 2026-05-12 — — CN disclosed
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 Agomab Spain, S.L.U. (ES) 2025-10-30 — — US disclosed
CN-114787145-B Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 阿戈麦布西班牙股份有限公司 2024-03-26 — — CN disclosed
CN-116323601-A 2- (3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 阿戈麦布西班牙股份有限公司 2023-06-23 — — CN disclosed
EP-4065572-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 Origo Biopharma, S.L. (ES) 2022-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 TGFBR2, TGFBR1, ACVR1 CYP1A2 3030/4885P2RX7 2717/4885LOXL2 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.